Rivaroxaban in nonvalvular AF: The advisory panel's perspective - TheHeart.Org PDF Print
TheHeart.Org
Rockville, MD - A new perspective highlights the regulatory considerations that the Food and Drug Administration (FDA) Cardiovascular and Renal Drugs Advisory Committee grappled with when the drug was evaluated last month [1]. As reported by heartwire,

...

 
Share |
Copyright © 2026 Global Dialysis. All Rights Reserved.